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Clinical relevance of silent red blood cell 
autoantibodies
The diagnosis of autoimmune hemolytic anemia
(AIHA) is based on the evidence of anemia, hemolysis
and the detection of red blood cell (RBCs) autoantibod-
ies.1-2 The absence of detectable RBC autoantibodies does
not always exclude autoimmune hemolysis. Conversely,
the presence of RBC autoantibodies is not always associ-
ated with hemolytic anemia. Silent RBC autoantibodies
have been detected in healthy blood donors,3,4 in preg-
nant females5 and in patients with autoimmune disor-
ders.6 While the occurrence of clinically non-significant
RBC autoantibodies is a well-known phenomenon in
immunohematology laboratories, there is little informa-
tion about the clinical course of subjects with silent RBC
autoantibodies and whether disorders known to be asso-
ciated with AHIA could also be present in these subjects.
To address these issues, we retrospectively analyzed the
characteristics and the long-term outcome of 60 subjects
with silent RBC autoantibodies who were referred to our
Hematology Center between January 1995 and
December 2012 and followed on a regular basis over
time.
Our results showed that the development of AHIA in
subjects with silent RBC autoantibodies was a rare event
and that disorders known to be associated with AHIA
were present in a relevant proportion of cases with silent
agglutinins.
Subjects with silent RBC autoantibodies showed nor-
mal Hb values, no signs of hemolysis, acrocyanosis
and/or Raynaud phenomena, and no previous history of
drugs known to be associated with AHIA, vaccinations,
infections, lymphoproliferative diseases or autoimmune
disorders. 
The initial assessment included complete blood count,
immunohematologic evaluation, reticulocyte count, hap-
toglobin, bilirubin, LDH, serum electrophoresis and clin-
ical examination. Data on blood counts, bilirubin levels
and immunohematologic tests performed during follow
up were also recorded. More details about the clinical
workout performed at baseline and during follow up are
reported in the Online Supplementary data.
Silent RBC autoantibodies were detected in 5 (8%)
pregnant females, 34 (57%) healthy individuals (blood
donors, 32; subjects with an abnormal agglutination of
blood samples, 2) and 21 (35%) subjects screened prior to
surgery (benign disorder, 16; malignancy, 5). 
The median follow up was 60 months (range, 10-204
months), the median age 48 years (range, 19-74 years),
and the median Hb value 138.5 g/L (range, 124-167 g/L)
with a median reticulocyte count of 74.5 x 109/L
(range:11.580-186000). Four blood donors showed an
increased reticulocyte count with Hb values ranging
between 130 and 160 g/L. Haptoglobin, bilirubin, and
LDH levels were normal in all cases (Table 1).
IgG autoantibodies were detected in 24 (40%) cases,
IgM in 35 (58%) and IgM+IgG in 1 (2%). Cold agglu-
tinins with a median titer of 1:512 and a thermal ampli-
tude around 30°C were recorded in 23/35 (66%) cases,
and warm agglutinins in 12 (34%). The median number
of immunohematologic tests per patient was 4 (range 2-
13) (Table 2). Clinical and serologic characteristics of sub-
jects with silent RBC autoantibodies according to the
associated condition or disorder are described in Figure 1.
Asymptomatic RBC autoantibodies were detected in 5
(8%) pregnant females at the time of the first trimester
screening (IgG 3 cases, IgM 1, IgG+IgM 1) and persisted
during and after pregnancy. No signs of hemolytic ane-
mia were observed in either the mothers or the new-
borns.
In 31 of the remaining 55 (56%) cases, no evidence of
an underlying disorder was observed, while it was pres-
ent in 24 (44%) cases; in 5 /21 (24%) with IgG autoanti-
bodies and in 19/34 (56%) with IgM autoantibodies 
(P<0.05).
Five (5/55, 9%) cancer-bearing subjects (breast cancer
2; thyroid cancer, 3) revealed silent RBC autoantibodies
(IgG, 2; IgM, 3) at the time of the pre-surgery screening
for cancer removal. RBC autoantibodies disappeared in 2
cases (IgG 1; IgM 1) after removal of thyroid cancer,
while they persisted in 3 with active disease.
The significant positivity of other autoantibodies
directed further serologic and clinical evaluations allow-
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Table 1. Clinical characteristics of subjects at the time of the first
detection of the silent red blood cell autoantibodies.
N (%)
No. of patients 60
Median follow up, months (range) 60 (10-204)
Gender M/F 33/27(55/45)
Median age, years (range) 48 (19-74)
Median Hb value, g/L (range) 138.5 (124-167)
Median reticulocytes x 109/L (range)1 7450 (11.580-186000)
Median bilirubin value mg/dl (range) 0.9 (0.4-1.2)
Median PLTS x 109/L (range) 237000 (135-396)
Framework in which the RBC autoantibodies were detected
Blood donation screening 32 (53)
Pre-surgery screening 21(35)
Pregnancy screening 5 (9)
Medical check-up1 2 (3)
F: females; M: males; Hb: hemoglobin; PLTS: platelets. 1Reticulocytes, normal
ranges: 22-139x109/L. Four blood donors with increased reticulocytes, and Hb values
ranging between 130 and 160 g/L. Two patients with abnormal agglutination of
blood samples. 
Table 2. Serological characteristics of the silent red blood cell
autoantibodies.
N (%)
No. of subjects with RBC autoantibodies 60 (100)
Median number of tests per subject 4 (2-13)
(range)
Warm IgG RBC autoantibodies 24/60 (40)
+complement 6/24 (25)
reactive eluate 24/24 (100)
IgM RBC autoantibodies 35/60 (58)
Cold IgM1 23/35 (66)
median titer at 4°C (range) 512 (1:128-1:4096)
+ complement 10/35 (43.5)
Warm IgM2 12/35 (34)
+complement 4/12 (33)
Warm IgG+IgM+C 1 (2)
RBC: red blood cell; Ig: immunoglobulin, C, complement. 1Thermal amplitude: until
32°C, 1 case; 22 cases <37°C. 2Thermal amplitude: 37°C.
ing the identification of an autoimmune disorder in 11
(11/55, 20%) subjects (Hashimoto thyroiditis, 4; anti-
phospholipid syndrome, 5; systemic lupus erythemato-
sus, 1; autoimmune glomerulonephritis, 1). IgM autoan-
tibodies were detected in the majority of cases (9/11
cases, 82%). 
Before surgery to remove colonic polyps, IgG RBC
autoantibodies associated with an active HCV hepatitis
were detected in 1 (1/55, 1.8%) patient. Both the HCV
virus and the RBC autoantibodies disappeared after treat-
ment with peg alpha2-interferon.
Bone marrow (BM) biopsy or aspirate with a flow-
cytometry analysis revealed the presence of a lympho-
proliferative disorder in 7 (7/55, 13%) cases, all with RBC
IgM autoantibodies (cold IgM, 4 cases; warm IgM, 3).  
A marginal zone lymphoma was diagnosed in 1 patient
who also showed enlarged abdominal lymph-nodes. In
the other 6 cases, all with no enlarged lymph-nodes, a
limited infiltration of small clonal B-lymphocytes was
detected in the BM. In all cases, monoclonal B-cell lym-
phocytes (MBLs) were also detected in the peripheral
blood by flow-cytometry. MBLs showed lymphoma-like
features in 3 cases and chronic lymphocytic leukemia-like
features in 3 (Online Supplementary Table S1). The median
MBL count was low (0.135 x109/L; range, 0.56-0.215
x109/L) and remained stable during follow up in 5 cases,
while it gradually increased over 10 years in 1. (Online
Supplementary Figure S1). None of these subjects devel-
oped a clinically overt lymphoma/chronic lymphocytic
leukemia.
The IgG autoantibodies disappeared in 10/24 (42%)
cases; in 7 subjects without an associated disorder, in 2
after the removal of a thyroid cancer and in 1 cured of the
HCV hepatitis. Agglutinins persisted in all cases after a
median follow up of 93 months (range,10-204). Only two
patients, both with agglutinins (2/60 total cases 3%; 2/35
IgM cases, 6%) and no evidence of a lymphoproliferative
disorder, experienced AHIA after 14 and 17 years, respec-
tively, from the first detection of cold autoantibodies.
Survival of subjects with silent agglutinins was lower,
though not significantly lower, than those with silent
warm autoantibodies (at 15 years, 75% vs. 100%; P=0.2)
(Online Supplementary Figure S2).
The retrospective nature of this study, and the fact that
not all cases with silent RBC were referred to our insti-
tute, should be underlined. This is an understandable
phenomenon as healthy subjects are not usually investi-
gated for asymptomatic RBC autoantibodies. The lack of
a denominator did not permit us to ascertain the inci-
dence and prevalence of silent autoantibodies among dif-
ferent patient populations. In addition, the number of
cases was too small to be able to define the relative dis-
tribution of different disease states among subjects with
silent RBC autoantibodies. 
The abnormal agglutination of blood samples in the
presence of cold agglutinins was common. This phenom-
enon was influenced both by the elapse of time from
obtaining samples and the temperature on storage. 
The development of a clinically manifest AHIA was
recorded in only 2 (6%) of the 35 subjects with asympto-
matic agglutinins. Multiple factors are likely to have
played a role in preventing hemolysis. As observed in
some cases of CAD, the complement pathway probably
could not be activated given the protective effect of the
physiological complement inhibitors CD55 and CD59 on
the RBC membrane.7 The lack of hemolysis could also be
due to an ineffective complement activation by some IgG
subclasses or binding by the FC-receptors of phagocytic
cells.7 In some cases, cross-reacting antiphospholipid
autoantibodies, adsorbing non-specifically onto the ery-
throcyte membrane, may be an incidental cause of false
positive tests.8 In addition, an effective erythropoiesis
could play a relevant compensatory effect in preventing
anemia.
As in a previous study,5 RBC autoantibodies detected in
5 pregnant females had no effect on the course of preg-
nancy, on the fetus development, or on the health of the
newborns.
An associated disorder was observed in 24 (44%) of the
remaining 55 cases and was significantly more frequent
in subjects with silent agglutinins. 
Given the known relationship between AHIA and
autoimmune diseases,6 cancers,9 HCV infection,10 and
lymphoproliferative disorders,11,12 the detection of these
conditions in subjects with silent RBC autoantibodies
was not surprising. 
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Figure 1. Serologic characteristics of subjects with silent red blood cell autoantibodies according to the associated condition or disorder. (1) Autoimmune dis-
orders: Hashimoto thyroiditis, 4 cases; anti-phospholipid syndrome, 5; systemic lupus erythematosus, 1; autoimmune glomerulonephritis, 1. (2)
Lymphoproliferative disorders: bone marrow involvement with MBL, 6 cases, marginal cell lymphoma, 1. (3) Cancers: breast cancer, 2; thyroid cancers, 3. 
A lymphoproliferative disorder was detected only in
subjects with silent agglutinins. Subjects with cold agglu-
tinin and a limited clonal B-cell disorder involving the BM
were described by Randen et al.13 as having a primary
cold agglutinin disease (CAD) or “cold agglutinin (CA)-
associated lymphoproliferative disease”. The 6 cases with
asymptomatic agglutinins, BM involvement and MBL
showed similar characteristics of primary CAD, even in
the absence of hemolytic anemia. Interestingly, none of
these subjects developed clinical signs of hemolysis or
clinical evidence of lymphoma during follow up. Low
count MBL have also been detected in patients with
AIHA, immune thrombocytopenic purpura,14 and in
healthy blood donors.15 Although a low count MBL is
associated with a negligible risk of progression to a lym-
phoproliferative disease, they may have a pathogenetic
relationship in the development of RBC autoantibodies. 
IgG autoantibodies disappeared after the cure of hepa-
titis in 1 patient and the removal of a thyroid cancer in 2.
This finding suggests that, in some cases, the removal of
an immune stimulation could have led to the clearance of
the autoantibodies. 
Taken together, the results of this study showed that in
subjects with silent RBC autoantibodies, the develop-
ment of a clinically overt AHIA was a rare event, while
disorders known to be associated with AHIA were pres-
ent in a relevant proportion of cases and more frequently
in subjects with silent agglutinins. 
Francesca R. Mauro,1 FabioTrastulli,1 Cristiano Alessandri,2
Guido Valesini,2 Gianluca Giovannetti,3 Costantino Riemma,1
Marika Porrazzo,1 Sara Pepe,1 Gioia Colafigli,1
Maria D. Caputo,1 Maria S. De Propris,1 Anna R. Guarini,1
Gabriella Girelli,3 Serelina Coluzzi3 and Robin Foà1
SC and RF contributed equally to this work.
1Hematology, Department of Cellular Biotechnologies and
Hematology, Policlinico Umberto 1, Sapienza University;
2Reumatologia, Dipartimento di Medicina Interna e Specialità
Mediche, Sapienza University and 3Immunohematology and
Transfusion Medicine Unit, Sapienza University, Rome, Italy 
Correspondence: mauro@bce.uniroma1.it
doi:10.3324/haematol.2017.177675
Information on authorship, contributions, and financial & other disclo-
sures was provided by the authors and is available with the online version
of this article at www.haematologica.org.
References
1. Packman CH. The clinical pictures of autoimmune hemolytic ane-
mia. Transfus Med Hemother. 2015;42(5):317-324.
2. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic ane-
mia. Blood. 2017;129(22):2971-2979.
3. Gorst DW, Rawlinson VI, Merry AH, Stratton F. Positive direct
antiglobulin test in normal individuals. Vox Sang. 1980;38(2):99–105.
4 Bareford D, Longster G, Gilks L, Tovey LA. Follow-up of normal
individuals with a positive antiglobulin test. Scand J Haematol.
1985;35(3):348-353. 
5. Hoppe B, Stibbe W, Bielefeld A, Pruss A, Salama A. Increased RBC
autoantibody production in pregnancy. Transfusion. 2001;
41(12):1559–1561.
6. Comellas-Kirkerup L, Hernández-Molina G, Cabral AR.
Antiphospholipid-associated thrombocytopenia or autoimmune
hemolytic anemia in patients with or without definite primary
antiphospholipid syndrome according to the Sapporo revised classi-
fication criteria: a 6-year follow-up study. Blood. 2010;116(16):3058-
3063.
7. Berentsen S. Complement, cold agglutinins, and therapy. Blood.
2014;123(26):4010-4012. 
8. Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospho-
lipid antibodies in systemic lupus erythematosus. Eur J Rheumatol.
2016;3(2):75-84.
9. Nenova IS, Valcheva MY, Beleva EA, et al. Autoimmune phenomena
in patients with solid tumors. Folia Medica (Plovdiv). 2016;58(3):195-
199.
10. Basseri RJ, Schmidt MT, Basseri B. Autoimmune hemolytic anemia
in treatment-naive chronic hepatitis C infection: a case report and
review of literature. Clin J Gastroenterol.  2010:3(5):237-2421.
11. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in
chronic lymphocytic leukemia: clinical, therapeutic, and prognostic
features. Blood. 2000;95(9):2786-2792. 
12. Barcellini W, Capalbo S, Agostinelli RM, et al. GIMEMA Chronic
Lymphocytic Leukemia Group. Relationship between autoimmune
phenomena and disease stage and therapy in B-cell chronic lympho-
cytic leukemia. Hematologica. 2006;91(12):689-692.
13. Randen U, Trøen G, Tierens A etal. Primary cold agglutinin-associat-
ed lymphoproliferative disease: a B-cell lymphoma of the bone mar-
row distinct from lymphoplasmacytic lymphoma. Haematologica.
2014;99(3):497-504.
14. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high
rate of CLL phenotype lymphocytes in autoimmune hemolytic ane-
mia and immune thrombocytopenic purpura. Hematologica. 2008;
93(1):151-152.
15. Shim YK, Rachel JM, Ghia P, et al. Monoclonal B-cell lymphocytosis
in healthy blood donors: an unexpectedly common finding. Blood.
2014;123(9):1319-1326.
haematologica 2017; 102:e475
LETTERS TO THE EDITOR
